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Evaluating the Impact of Pharmacist Pharmacotherapy Service on Hepatitis C Outcomes within a Large
Integrated Health-System
Jessica Hendrix, PharmD; Charmaine Hunt, PharmD, MS; Judy Perkins, RPH, BCACP

Background
• The World Health Organization (WHO) estimates that
58 million people worldwide are chronically infected
with hepatitis C virus (HCV) as of 2019 and
approximately 1.5 million new infections each year.1
• Despite antiviral medications demonstrating cure
rates >90% in persons with HCV infection, the
diagnosis and subsequent treatment remain low. Of
the 58 million people living with HCV, approximately
21% (15.2 million) were aware of their diagnosis, and
of those, 62% (9.4 million) had been treated with
direct acting antivirals (DAAs) by the end of 2019.1,2
• Guidelines for treatment of HCV change often in
response to new drugs coming to market and
published clinical trial data. Drug treatment decisions
are often driven by patient specific factors that are
both clinical and financial (i.e., payers).
• Clinical pharmacists provide evidence-based care to
patients and allow primary care providers and
gastroenterologists to focus on other aspects of
patient care.

Purpose
• The purpose of this study is to measure the rate of
HCV cure and to characterize the impact of
services provided and the added value of the
pharmacist. Hepatitis C cure is defined as
sustained virologic response at least 12 weeks
after treatment (i.e., SVR12).

Study Population Baseline Characteristics
(n=198)
Demographic

125 (63)
73 (37)

HCV Genotype
1
1a
1b
2
2a
2b
3a
4
6
6a

8 (4)
98 (49)
28 (14)
8 (4)
6 (3)
29 (15)
14 (7)
4 (2)
2 (1)
1 (<1)

Direct Acting Antiviral
Glecaprevir-Pibrentasvir
Ledipasvir-Sofosbuvir
Sofosbuvir-Velpatasvir
Sofosbuvir-Velpatasvir Voxilaprevir

137 (69)
33 (17)
21 (11)
7 (3)

Design
• Retrospective data collection study
• Review of EPIC electronic health record (EHR) of
patients referred for HCV treatment consideration
from June 20th, 2017, to June 2021
Population
•Criteria for Inclusion
•Patients referred to pharmacotherapy clinic for
treatment consideration of Hepatitis C virus
•Criteria for Exclusion
•Pregnancy
•Incarceration

• A Pharmacotherapy service for patients with HCV
offers the unique benefit of pharmacist clinical
guidance, optimized operational flow, and outcomes
tracking. These are all important factors in
determining costs as well as cure rates for patients
and payers.
• The preliminary results of this study show reasons
for treatment failure include breakthrough infection
(n=1), missing SVR12 data (n=4), and loss to follow
up(n=11). The breakthrough infection was
determined by the patient having a detectable viral
load at 12 weeks post treatment. In four patients it
was cost prohibitive to obtain 12-week labs due to
lack of insurance or other financial resources. These
four patients were classified as treatment failures
due to missing SVR12 data. Eleven patients in the
preliminary analysis failed treatment because of loss
to follow up as they did not come in for 12-week
labs and were off serviced by the pharmacotherapy
clinic.

Preliminary Results
Distribution of Patients that
achieved HCV Cure (n=198)

Distribution of Interventions made
by the Pharmacist (%)

16
40.4%

Primary
• To determine the rate of Hepatitis C cure vs
treatment failure

Methods

• From 2015-2018 an estimated 40% of people living
in the US were unaware they were infected with
HCV. Treatment with DAAs can cure HCV infection in
more than 90% of patients, however reaching more
people with HCV is a critical component of
preventing transmission and saving lives.3,4

Number of Patients n (%)

Male
Female

Outcomes

Secondary
• Determine the impact of services provided and
the added value of the pharmacist within the
Providence Oregon Pharmacotherapy Service
Program

Discussion

• Results and conclusions are ongoing and will be
shared upon project completion in June 2022. All
data collection and analysis are being conducted
under the approval of the PSJH institutional review
board IRB# STUDY2022000075

51.6%
182
Cure

8.1%

Fail
DDIs

Compliance

Labs

Distribution of Reasons for
treatment failure (n=16)

Conclusion
Distribution of Interventions made
by the Pharmacist (n=198)
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• Pharmacist interventions were captured for all
patients encounters (n=198) and included drug drug
interactions, coordination and/or facilitation of lab
scheduling, and compliance. Preliminary results
indicate that most Interventions were related to
labs (51.6%) followed by drug interactions (40.4%)
and then compliance (8.1%).
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• Results and conclusion are ongoing and will be shared
upon project completion. Preliminary analysis indicates
that utilization of the pharmacist is a highly effective
and safe way of using DAAs for treatment of patients
with HCV.
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